Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading cross-functional teams Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, who will […]
continue readingCollaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability Customers can gain access to Touchlight’s dbDNA as an integral part of Lonza’s offering, benefiting from end-to-end […]
continue readingIn H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook 2022 confirmed at low to mid-teens CER sales growth and CORE EBITDA margin improvement Mid-Term […]
continue reading
. Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who is retiring from Lonza Lonza today announced that its Board of Directors has appointed Maria […]
continue reading
. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak’s lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion of the facility in March 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed […]
continue readingShareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year A dividend of CHF 3.00 per share will be paid out […]
continue reading. Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors Stable dividend of CHF 3.00 per share proposed 2021 Annual and Sustainability Reports published Lonza today announced the publication of its 2021 Annual and […]
continue reading
. Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses He will commence his tenure with Lonza Group on 1 July 2022 Christian succeeds Claude Dartiguelongue who retires […]
continue readingLonza erzielt einen Umsatz von CHF 5.4 Milliarden und einem Umsatzwachstum von 20% (kWk)1 CHF 1.7 Milliarden Kern-EBITDA resultieren in einer Marge von 30,8% 2021 erreichten die Investitionsausgaben 24% des Umsatzes und unterstützten den langfristigen Plan durch risikoarme Wachstumsinvestitionen attraktive Margen zu erzielen Weiterhin Konzentration auf operative Spitzenleistungen und die Durchführung von Wachstumsprojekten Ausblick für […]
continue readingLonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 2021 CAPEX reached 24% of sales, supporting long-term plan to deliver attractive margins through de-risked growth investments Continuing focus on operational excellence and execution of growth projects Outlook 2022: low to mid-teens CER sales […]
continue reading